Furthermore, the recent success of the RNAi-based drug Cand5 in the treatment of age-related macular degeneration (Tolentino et al, 2004) highlights the vast potential for RNAi-based drugs in the treatment of a variety of diseases and the current study suggests that a PTHrP-specific siRNA could be similarly effective. The gene discussed is PTHLH; the disease is age-related macular degeneration.